Altimmune, Inc. (NASDAQ:ALT) Receives $16.60 Average Target Price from Analysts

Altimmune, Inc. (NASDAQ:ALT) has received a consensus recommendation of “Hold” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.60.

A number of research firms recently issued reports on ALT. Citizens Jmp cut their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Monday, October 20th.

Insider Buying and Selling at Altimmune

In other news, Director Jerome Benedict Durso acquired 12,500 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the transaction, the director directly owned 12,500 shares in the company, valued at $51,625. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Gill acquired 12,500 shares of the company’s stock in a transaction on Tuesday, December 23rd. The shares were purchased at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,250. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 30,527 shares of company stock valued at $125,278 over the last three months. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after purchasing an additional 2,241 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after purchasing an additional 2,748 shares during the period. Concurrent Investment Advisors LLC lifted its holdings in shares of Altimmune by 16.4% in the second quarter. Concurrent Investment Advisors LLC now owns 25,258 shares of the company’s stock valued at $98,000 after purchasing an additional 3,565 shares in the last quarter. Summit Financial Wealth Advisors LLC boosted its position in shares of Altimmune by 4.2% during the second quarter. Summit Financial Wealth Advisors LLC now owns 122,988 shares of the company’s stock worth $476,000 after buying an additional 5,000 shares during the period. Finally, Kingswood Wealth Advisors LLC boosted its position in shares of Altimmune by 48.1% during the third quarter. Kingswood Wealth Advisors LLC now owns 15,400 shares of the company’s stock worth $58,000 after buying an additional 5,000 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Performance

NASDAQ:ALT opened at $4.62 on Friday. The stock has a market capitalization of $482.05 million, a P/E ratio of -4.32 and a beta of 0.04. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. Altimmune has a 1 year low of $2.90 and a 1 year high of $7.73. The firm has a 50 day moving average of $4.52 and a 200-day moving average of $4.10.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. As a group, sell-side analysts anticipate that Altimmune will post -1.35 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.